This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy?
To begin the month, it was situated within penny stock territory, priced below sixty cents. However, by the end of last week, it had surged to more than four dollars and fifty cents, propelled by some positive advancements. Remarkably, it skyrocketed over 600% in less than a week, but its market capitalization remains approximately $2 billion at this moment.